First Drug Designed With Generative AI Enters Phase II Trial

INS018_055 received positive topline data in Phase I in early 2023 (1^✔ ✔Trusted Source
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

). In Phase I trials carried out in New Zealand and China, INS018_055 was tested in 78 and 48 healthy subjects, divided into cohorts focusing on a single ascending dose (SAD) study and multiple ascending dose (MAD) study. The international multi-sites Phase I studies yielded consistent results, demonstrating favorable safety, tolerability, and pharmacokinetics (PK) profiles of INS018_055, supporting the initiation of the Phase II study.

“With demonstrated potential against both fibrosis and inflammation, INS018_055 could offer another option for patients worldwide,” said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “The achievement of the first dose for INS018_055 in the Phase II clinical trial is not only an important step for Insilico, but also a milestone for AI-driven drug discovery and development. Together, we are expecting more achievements powered by AI for global unmet medical needs.”

Insilico Medicine Wants to Show Value of Generative AI in Drug Discovery

“When we started developing generative AI for drug discovery, I never expected to see the clinical and preclinical results we have today,” said Alex Zhavoronkov, PhD, Founder and co-CEO of Insilico Medicine. “Initiating Phase II trials with this novel inhibitor for IPF represents a major milestone for deep generative reinforcement learning in drug discovery. We will explore the efficacy for patients of AI-discovered and designed treatments in clinical trials, which is a true validation of our generative AI platform. We are eager to continue to advance this potentially first-in-class therapy forward to help patients in need and show the value of generative AI in drug discovery and development.”

Insilico is one of the pioneers in utilizing generative AI for drug discovery and development. The company first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.

AI platform, which includes generative biology, chemistry, and medicine. Moreover, Insilico Medicine launched its target discovery AI platform PandaOmics, generative chemistry AI platform Chemistry42, and clinical trial analysis platform inClinico commercially to enable the biotechnology and the pharmaceutical industry to utilize these advanced generative AI tools to power their internal research and development.

Insilico is delivering breakthroughs for healthcare in multiple disease areas using generative AI. Since 2021, Insilico has nominated and announced 12 preclinical candidates in its comprehensive portfolio of over 30 assets and has advanced 3 of them to the clinical stage. The Company has benefited from a technology collaboration with NVIDIA, including NVIDIA DGX systems.

“When we started, there were hundreds of companies claiming to use AI for drug discovery,” says Zhavoronkov. “Insilico was started as a deep learning pureplay at NVIDIA GTC, a global conference on AI and the metaverse. We were one of the first to get the DevBox, test the latest hardware early, and now work on NVIDIA DGX. We made a bet on generative AI early, tapped NVIDIA’s best-in-class technology, worked hard, and now we can tangibly demonstrate substantial R&D performance boosts and real clinical-stage drugs imagined by AI.”

Reference :

1. A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects – (https://classic.clinicaltrials.gov/ct2/show/NCT05154240)

Source: Eurekalert